STAT+: NIH to move last group of its research chimps to a sanctuary
The last chimpanzees owned by the U.S. government and still living in a laboratory will be moved to a sanctuary next year.
STAT PlusPharmalot NIH to move last group of its research chimps to a sanctuary Move comes a decade after the agency agreed to end funding for biomedical research on chimps Manage alerts for this article Save this story for later Share this article By Ed SilvermanNov. 18, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.
The last chimpanzees owned by the U.S. government and still living in a laboratory will be moved to a sanctuary next year, a move that comes more than a decade after the National Institutes of Health agreed to end its funding for biomedical research on chimpanzees. Beginning early next year, nearly three dozen chimpanzees housed at the Keeling Center for Comparative Medicine and Research in Bastrop, Texas, will be transferred a 200-acre federal sanctuary operated by Chimp Haven, in Keithville, La., which is the only such sanctuary in the U.S.Advertisement “Completing their transfers will fulfill NIH’s commitment, announced in November 2015, to retire all NIH-owned chimpanzees to sanctuary,” said NIH Director Jay Bhattacharya in a statement.
STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account?
Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.
Subscribe Log In Pharmaceuticals, Policy, research, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter From the lab to the medicine chest, these are the must-read drug industry updates of the day Recommended Pharmalot November 18, 2026 STAT Plus: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more Pharmalot November 17, 2026 STAT Plus: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more Advertisement Pharmalot November 16, 2026 STAT Plus: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns Pharmalot November 16, 2026 STAT Plus: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more Pharmalot November 13, 2026 STAT Plus: Up and down the ladder: The latest comings and goings Subscriber Picks
comments(0)
5-min edit window · permanent after that